Key points are not available for this paper at this time.
(A-B) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (C-D) Flow cytometry analysis of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells in the presence of recombinant CCL2 protein or CCL2 neutralizing antibody. (E-F) Chemotaxis assays showing the effect of CCL2 signaling on SLAMF7-regulated migration of macrophages using the indicated treatments. (G) Left: Gross appearance of the liver bearing orthotopic HCC tumors in the indicated treatment groups. Right: The tumor weight and tumor volume of each group (5 mice per group). (H) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD11b+ F4/80+ CD206+ macrophages in the indicated treatment groups. *P
Weng et al. (Tue,) studied this question.